This content is in French.
Fasting hyperglycemia: a silent cancer risk factor?
15 octobre 2025
By Ana Espino | Published on October 15, 2025 | 2 min readFasting hyperglycemia (FHG)—defined as elevated blood glucose levels outside of meals—is a common condition, particularly among individuals with type 2 diabetes or metabolic syndrome. Its role in the development of cardiovascular diseases is well established, but its involvement in oncogenesis remains controversial and poorly understood. Am
By Ana Espino | Published on October 15, 2025 | 2 min read
Fasting hyperglycemia (FHG)—defined as elevated blood glucose levels outside of meals—is a common condition, particularly among individuals with type 2 diabetes or metabolic syndrome. Its role in the development of cardiovascular diseases is well established, but its involvement in oncogenesis remains controversial and poorly understood.
Fasting hyperglycemia (FHG)—defined as elevated blood glucose levels outside of meals—is a common condition, particularly among individuals with type 2 diabetes or metabolic syndrome. Its role in the development of cardiovascular diseases is well established, but its involvement in oncogenesis remains controversial and poorly understood.
Among current esearch limitations is the lack of a robust quantification of the level of evidence linking FHG to specific cancers. Challenges include the complexity of metabolic mechanisms involved, the variability of epidemiological data, and the difficulty in isolating the effect of blood glucose from that of other confounding factors such as body weight, physical activity, and insulin levels.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Teixeira, P. P., et al (2025). A burden of proof study of the effects of exposure to high fasting plasma glucose on the risk of seven types of cancer. Scientific reports, 15(1), 28859
View the source
